203 related articles for article (PubMed ID: 17727947)
1. Induction of late graft-versus-host disease in a patient post-allogeneic stem cell transplantation by progesterone in conjunction with donor lymphocyte infusion.
Gesundheit B; Shapira MY; Maly A; Samuel S; Budowski E; Or R
Leuk Res; 2008 Mar; 32(3):501-3. PubMed ID: 17727947
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
Huff CA; Fuchs EJ; Smith BD; Blackford A; Garrett-Mayer E; Brodsky RA; Flinn IW; Ambinder RF; Borrello IM; Matsui WH; Vogelsang GB; Griffin CA; Luznik L; Jones RJ
Biol Blood Marrow Transplant; 2006 Apr; 12(4):414-21. PubMed ID: 16545725
[TBL] [Abstract][Full Text] [Related]
4. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
[TBL] [Abstract][Full Text] [Related]
5. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
[TBL] [Abstract][Full Text] [Related]
7. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
Loren AW; Porter DL
Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
[TBL] [Abstract][Full Text] [Related]
9. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
[TBL] [Abstract][Full Text] [Related]
10. Severe intestinal graft versus host disease after donor lymphocyte infusion; response to extracorporeal photochemotherapy.
Vural F; Donmez A; Doganavşargil B; Cagýrgan S; Alper H; Tombuloglu M
Transfus Apher Sci; 2005 Oct; 33(2):129-33. PubMed ID: 16150645
[TBL] [Abstract][Full Text] [Related]
11. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
[TBL] [Abstract][Full Text] [Related]
12. [Methotrexate for treatment of graft versus host disease after allogeneic hematopoietic stem cell transplantation].
Huang XJ; Jiang Q; Chen H; Xu LP; Liu DH; Chen YH; Han W; Zhang YC; Liu KY; Lu DP
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1097-101. PubMed ID: 16029565
[TBL] [Abstract][Full Text] [Related]
13. Severe eosinophilia as a manifestation of acute graft-versus-host disease.
Paralkar VR; Goradia A; Luger SM; Loren AW
Oncology; 2008; 75(3-4):134-6. PubMed ID: 18791329
[TBL] [Abstract][Full Text] [Related]
14. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
[TBL] [Abstract][Full Text] [Related]
15. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S
Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
[TBL] [Abstract][Full Text] [Related]
16. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
17. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose.
Fozza C; Szydlo RM; Abdel-Rehim MM; Nadal E; Goldman JM; Apperley JF; Dazzi F
Br J Haematol; 2007 Mar; 136(6):833-6. PubMed ID: 17341269
[TBL] [Abstract][Full Text] [Related]
18. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
19. Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect.
Alyea EP
Best Pract Res Clin Haematol; 2008 Jun; 21(2):239-50. PubMed ID: 18503989
[TBL] [Abstract][Full Text] [Related]
20. Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation.
Schlaak M; Kurschat P; Shimabukuro-Vornhagen A; Scheid C; Chemnitz J; Stadler R; von Bergwelt-Baildon M; Theurich S
Transpl Immunol; 2011 Sep; 25(2-3):163-6. PubMed ID: 21745569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
